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ABSTRACT
While bivalent and quadrivalent HPV vaccines have been used for about 10 years, a nonavalent vaccine
against HPV types 6/11/16/18/31/33/45/52 and 58 has been recently approved by FDA and EMA and is now
commercially available. The objective of our study was to evaluate the potential impact of the nonavalent
vaccine on HPV infection and related low- and high-grade squamous intraepithelial lesions (LSIL, HSIL),
compared to the impact of the quadrivalent vaccine, in a female population living in Sicily (Italy).
Low estimates of HPV vaccine impact were calculated as prevalence of HPV 6/11/16/18/31/33/45/52 and
58 genotypes, alone or in association, but excluding presence of other HPV types; high estimates were
calculated as prevalence of HPV 6/11/16/18/31/33/45/52 and 58 genotypes alone or in association, in the
presence of other HPV types.
The nonavalent HPV vaccine showed increased impact, compared to the quadrivalent vaccine.
Estimates of potential impact varied from 30.9% (low estimate) to 53.3% (high estimate) for LSIL, and from
56.9% to 81,0% for HSIL. The proportion of additional cases potentially prevented by the nonavalent
vaccine was 14.4%–23.8% for LSIL, and 19.0%–32.8% for HSIL.
The beneﬁt of the nonavalent vaccine compared to the quadrivalent vaccine was more than 80% for
both low and high impact estimates for LSIL and more than 50% for both low and high impact estimates
for HSIL.
The present study conﬁrms that the switch from a ﬁrst generation HPV vaccines to a nonavalent vaccine
would increase the prevention of cervical HSIL in up to 90% of cases.
KEYWORDS
HPV infection; impact
estimate; nonavalent;
quadrivalent; squamous
intraepithelial lesions;
vaccine
Introduction
Demonstration of the role of persistent infection with high-risk
(HR) Human Papillomaviruses (HPV) as the causal agent of
cervical cancer1 made the development of ﬁrst and second gen-
eration prophylactic vaccines possible.2,3 In addition to cervical
carcinoma, HR HPV, such as HPV 16 and 18, are considered
responsible for a signiﬁcant number of cervical low- and high-
grade squamous intraepithelial lesions (LSIL and HSIL, respec-
tively), as well as a subset of cancers of the vulva, vagina, penis
and anus,4,5,67 and also a subset of neoplastic lesions of head
and neck. On the other hand, infection with low-risk (LR)
HPV types, such as HPV 16 and 11 genotypes, is associated
with 90% of anogenital warts in men and women. Furthermore,
a subset of neoplastic lesions of the head and neck and all geni-
tal warts in men and women8 and also causes recurrent respira-
tory papillomatosis, a very difﬁcult to treat pathological entity
with high recurrence rates.9
Two HPV vaccines have been licensed and are at the
moment available in Europe: the bivalent (Cervarix, GSK
biologicals) HPV vaccine, which prevents infections with the
HR HPV 16 and 18; and the quadrivalent HPV vaccine,
(Gardasil, Sanoﬁ Pasteur MSD), which, in addition to HR 16
and 18, also targets the LR HPV 6 and 11. Both vaccines in clin-
ical trials exhibited a high level of clinical efﬁcacy associated
with a reassuring safety proﬁle.10,11
Recently, the FDA (2014) and EMA (2015) approved a non-
avalent HPV vaccine (Merk, Sanoﬁ Pasteur MSD, 9vHPV,
trade name Gardasil9) which, in addition to the four genotypes
of the quadrivalent vaccine, also targets ﬁve additional HR gen-
otypes, namely, HPV 31/33/45/52/58, which are the most fre-
quently detected types in invasive cervical cancer wordlwide,
after HPV 16 and HPV 18.12,13
In a previous report, the nonavalent vaccine exhibited an
efﬁcacy of 96.7% in preventing cervical, vaginal and vulvar
HSIL related to the newly added HPV genotypes, while con-
ﬁrming the clinical efﬁcacy and safety proﬁle of the quadriva-
lent vaccine.14 Moreover, Serrano et al. estimated that the
addition of HPV 31/33/45/52 and 58 to the genotypes already
included in the quadrivalent vaccines could expand the preven-
tion of invasive cervical cancers worldwide from 70% to 90%.15
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Also, a recent systematic review and meta-analysis,16 sug-
gested a potential for the nonavalent vaccine to further reduce
precancerous lesions and cervical cancer.17,18
The aim of our study was to evaluate the potential impact of
a candidate nonavalent HPV vaccine on HPV infection and
HPV-related HSIL and LSIL, compared with the presently uti-
lized quadrivalent HPV vaccine, in a female population living
in Sicily, southern Italy.
Results
Of the 1794 samples with a positive HPV ﬁnding, 1244
(69.3%) were single infections and 550 (30.6%) multiple infec-
tions. HR HPV types, alone or in combined infection with LR
types, were present in 1466 (81.7%) samples. A total of 37
HPV types were identiﬁed, of which 21 were HR HPV types
and 16 LR HPV types (Fig. 1). As far as the HPV types com-
prised in the nonavalent vaccine were concerned, detection
rates were 22.2% for HPV 16, 4.8% for HPV 18, 9.0% for
HPV 31, 2.6% for HPV 33, 3.2% for HPV 45, 8.6% for HPV
52, 4.4% for HPV 58, 6.8% for HPV 6 and 0.8% for HPV 11.
Altogether, 584/1794 (32.5%) samples harboured at least one
of the four HPV types covered by the current quadrivalent
vaccine (HPV 6/11/16 and 18), while 984 (54.8%) samples
harboured at least one of the nine genotypes included in non-
avalent vaccine, implying a signiﬁcantly higher estimated cov-
erage of HPV infection from the nonavalent vaccine than the
current quadrivalent vaccine (54.8% vs 32.5%; p<0.001).
Of the 501 samples with a known histological diagnosis of
LSIL, a total of 362 LSIL were HPV positive. The most fre-
quently detected type was HPV 16, found in 14.8% of LSIL; fre-
quencies for types other than HPV 16 that are contained in the
nonavalent vaccine were 4.4% for HPV 6, 0.8% for HPV 11,
3.8% for HPV 18, 9.2% for HPV 31, 2% for HPV 33, 2.8% for
HPV 45, 5.4% for HPV 52 and 3.8.% for HPV 58. Of the 64
cases of HSIL diagnoses, a total of 58 (90.6%) were HPV posi-
tive. The most frequently detected type was HPV 16, found in
42.2% of HSIL; frequencies for types other than HPV 16 that
are contained in the nonavalent vaccine were 3.1% for HPV 6,
1.6% for HPV 18, 12.5% for HPV 31, 7.8% for HPV 33, 4.7%
for HPV 45, 6.2% for HPV 52 and 3.1% for HPV 58 (Table 1).
The potential impact of the quadrivalent and nonavalent
HPV vaccines on LSIL and HSIL histological diagnoses, as
assessed by low and high impact estimates, is presented in
Table 2 and Fig. 2. The nonavalent HPV vaccine showed
increased impact on both categories of lesions, compared to the
quadrivalent vaccine. As far as LSIL were concerned, the
number of HPV infection with genotypes targeted by the quad-
rivalent vaccine varied between 16.6% (low estimate) and
29.6% (high estimate) while the proportion of those associated
with genotypes targeted by the nonavalent vaccine varied
between 30.9% (low estimate) and 53.3% (high estimate). The
absolute additional impact of the nonavalent vaccine was statis-
tically signiﬁcant by low (14.4%) and high impact estimate
(23.8%). The beneﬁt of the nonavalent vaccine compared to the
quadrivalent vaccine, as shown by the relative additional poten-
tial impact, was 80% for either low or high impact estimates.
As far as histological HSIL were concerned, the number of
HPV genotypes targeted by the quadrivalent vaccine varied
between 37.9% (low estimate) and 48.3% (high estimate); the
number of viral genotypes targeted by the nonavalent vaccine
Figure 1. Type-speciﬁc distribution of high-risk and low risk HPV among 1794 women HPVC.
Table 1. n (%) HPV-types in histological diagnosis.
LSILc HSILd
LR-HPVa n (%) n (%)
6 22 (4.4) 2(3.1)
11 4 (0.8) —
40 5 (1) 2(3.1)
42 15 (2.3) 3(4.7)
54 13 (2.6) 2(3.1)
55 2 (0.4) —
61 16 (3.2) 1 (1.6)
62 19 (3.8) 2(3.1)
71 2 (0.4) —
81 7 (1.4) 2(3.1)
83 4 (0.8) —
84 10 (2) —
89 11 (2.2) —
HR-HPVb
16 74 (14.8) 27(42.2)
18 19 (3.8) 1 (1.6)
31 46 (9.2) 8(12.5)
33 10 (2.0) 5 (7.8)
35 5 (1) —
39 8 (1.6) —
45 14 (2.8) 3 (4.7)
51 41 (8.2) 3 (4.7)
52 27(5.4) 4 (6.2)
53 36 (7.2) 2 (3.1)
56 17 (3.4) 2 (3.1)
58 19 (3.8) 2 (3.1)
59 21 (4.2) 2 (3.1)
66 50 (10) 2 (3.1)
67 1 (0.2) —
68 7 (1.4) —
69 1(0.2) —
70 4 (0.8) 1(1.6)
73 14 (2.8) —
82 3(0.6) —
aD Low-risk HPV genotype; bD High-risk HPV genotype; cD Low-grade squamous
intraepithelial lesions; dD High-grade squamous intraepithelial lesions
1840 G. CAPRA ET AL.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ita
 di
 Pa
ler
mo
] a
t 2
2:5
4 2
7 A
ug
us
t 2
01
7 
varied between 56.9% (low estimate) and 81.0% (high estimate).
The absolute additional impact of the nonavalent vaccine was
signiﬁcant by low (19.0%) and high impact estimate (32.8%).
The beneﬁt of the nonavalent vaccine compared to the quadri-
valent vaccine, as shown by the relative additional potential
impact, was 50% for low and high impact estimates.
Discussion
In a recent European study, the estimated annual number of
new cervical cancers in 2013 was 34,7089; approximately 50%
of cases being caused by HPV 16/18 and 25% by HPV 31/33/
45/52/58.19
The International Agency for Research on Cancer (IARC)
has identiﬁed twelve HPV types as carcinogenic to
humans: HPV16/18/31/33/35/39/45/51/52/56/58/59.20 There-
fore, assuming a 100% vaccine efﬁcacy and coverage, estima-
tion of the epidemiological burden of HPV-related cervical
cancers and precancerous SIL suggests that the ﬁrst generation,
bivalent and quadrivalent vaccines targeted against HR-HPV16
and 18 could prevent 25,267 cervical cancers, accounting for
72.8% of total European cases.9
As being HSIL identiﬁed as the precursors of cervical cancer,
they are considered appropriate as surrogate outcomes to eval-
uate HPV vaccine efﬁcacy against cervical cancer worldwide.
Nevertheless, in this study the impact of ﬁrst (quadrivalent)
and second (nonavalent) generation of HPV vaccines was also
evaluated on cervical LSIL, notwithstanding the fact that LSIL
are not considered as precancerous lesions. Indeed, taking also
into consideration psychological impact on HPV infected
women and economic potential burden due to medical follow-
up and treatment, the assessment of HPV vaccines on LSIL
development may be worthwhile.
In general, the attribution of cervical lesions to speciﬁc
HPV genotypes is complicated by the occurrence of infections
with multiple HPV types in the same lesion; therefore, the
potential beneﬁt of a HPV vaccine is not easily assessable,
especially when viral types not prevented by vaccination are
also detected in the same lesion. In this study, therefore, the
impact of the vaccine was measured by low and high esti-
mates, considering the presence of single or multiple HPV
infections, following a previous approach.10 However, since
high estimate considers that the HPV types targeted by vac-
cine are the cause of a lesion even when they are associated
with other viral genotypes, the risk exists that high estimate
may lead to overestimation of the degree of effectiveness of
the vaccine. Therefore, it can be reasonably assumed that the
real potential impact of vaccine is in the middle between high
and low estimates.
In the group of LSIL tested in our study, the beneﬁt of the
nonavalent vaccine with respect to cervical lesion as tested in
our study, the beneﬁt of the vaccine with respect to quadriva-
lent vaccine was 80% for either low and high impact esti-
mates, while in the group of HSIL was 50% for either low and
high impact estimates. With high estimate calculations, the
overall additional impact of HPV vaccine nonavalent was
Table 2. Overall Proportion (Low and High Estimates) of HSIL targeted by quadrivalent and nonavalent vaccines.
Low Estimate High Estimate
Histologically diagnosed LSIL n (%; 95% CI) n(%; 95% CI)
(ND362) Quadrivalent vaccine 60 (16.6; [12.7–20.4]) 107 (29.6; [24.9–34.3])
Nonavalent vaccine 112 (30.9; [26.2–35.7]) 193 (53.3; [48.2–58.5])
Absolute additional impact (% of additional prevented cases) 14.4% (p<0.001) 23.8% (p<0.001)
Relative additional impact (%) 86.7% 80.0%
Histologically diagnosed HSIL
(ND58) Quadrivalent vaccine 22 (37.9; [25.4–50.4]) 28 (48.3; [35.4–61.1])
Nonavalent vaccine 33 (56.9; [44.2–69.6]) 47 (81.0; [70.9–91.1])
Absolute additional Impact (% of additional prevented cases) 19.0% (pD0.0408) 32.8% (pD0.0002)
Relative additional impact (%) 50.0% 67.9%
Figure 2. Potential impact of quadrivalent and nonavalent HPV vaccines on LSIL and HSIL histological diagnosis.
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remarkable for lesions effectively prevented by the second gen-
eration vaccine HPV (additional absolute impact).
The Edith III study,21 showed that from 43% (low estimate)
to 65% (high estimate) of cervical HSIL were associated with
HPV types targeted from the quadrivalent vaccine. In a recent
study on potential impact of a nonavalent vaccine on the occur-
rence of HPV related diseases, the authors showed that the sec-
ond generation vaccine could prevent from 77% to 90% of
cervical HSIL.10 This potential beneﬁt on the prevention of all
grades of cervical lesions could have a positive impact on the
public health systems by reducing total costs related to the
management of these lesions.
In conclusion, the present study on a female population in
Sicily (southern Italy) conﬁrms, in accordance with previous
result (17), that the switch from a bivalent or quadrivalent (ﬁrst
generation HPV vaccines) to (second generation) a nonavalent
HPV vaccine, would increase the prevention of high and low
grade cervical lesions up to 90% and to 60% of cases respec-
tively, offering a much wider protection.
It should be stressed that a signiﬁcant reduction in precan-
cerous lesions and HPV-related tumors can be reached only if
vaccination coverage reaches more than 80%.22
Implementation of nonavalent vaccination programs could
become, thus, a cost effective public health prevention
approach, based on the potential to produce substantial incre-
mental beneﬁt.
Methods
Study subjects
The analysis involved samples from 4376 patients who consec-
utively came to the Virology laboratory of the Department of
Sciences for Health Promotion and Mother and Child Care
(Policlinico University of Palermo, Italy), between January
2010 and December 2015, with a request for HPV testing by
their doctor. All samples were from women attending different
gynecology outpatient clinics or private practice gynaecologists.
Women were asked for information on their diagnosis of cervi-
cal disease, if any. All cervical samples were tested for HPV
DNA presence as described below; cases of histologically con-
ﬁrmed diagnosis of cervical LSIL and HSIL or cancer (HSIL)
were registered and the samples were evaluated as described
below. All participants signed written, informed consent prior
to entering the study. The informed consent and the study pro-
tocol were approved by the institutional review board at the
Policlinico University of Palermo.
Clinical samples
Routine laboratory diagnosis of HPV infection was performed
on all samples using routine laboratory procedures.23 DNA was
extracted by the use of a QIAampMini Kit (Qiagen). HPV detec-
tion was carried out with the Linear ArrayHPV Genotyping Test
(Roche Diagnostics), which allows the identiﬁcation of 16 types
considered as LR HPV (HPV 6, HPV 11, HPV 40, HPV 42,
HPV 54, HPV 55, HPV 61, HPV 62, HPV 64, HPV 71, HPV 72,
HPV 81, HPV 83, HPV 84, HPV 87 and HPV 89) and 21 types
(HPV 16, HPV 18, HPV 26, HPV 31, HPV 33, HPV 35, HPV 39,
HPV 45, HPV 51, HPV 52, HPV 53, HPV 56, HPV 58, HPV 59,
HPV 66, HPV 67, HPV 68, HPV 69, HPV 70, HPV 73, and HPV
82) considered as deﬁnitive or probable HR HPV types.24,25
Since Linear Array HPV is unable to correctly determine HPV
52 status in women co-infected with either HPV 33, 35, and/or
HPV 58,26 samples with ambiguous HPV 52 status were retested
with the INNO-LiPA HPV assay (Innogenetics), and only those
cases conﬁrmed HPV 52 with this assay were considered as truly
positive for HPV5227 and included in the assay.
After HPV testing and evaluation of histological diagnoses,
three series of cervical samples were selected and examined as
follows:
 Group I: 1794 consecutive samples with a positive HPV
result, to evaluate the impact of the two vaccines on HPV
infection rate, independently of the presence of cervical
SILs,;
 Group II: 501 consecutive samples with histologically
diagnosed LSIL;
 Group III: 59 consecutive samples with HSIL and 5 carci-
noma in situ, as histologically diagnosed. For ease of com-
putation, these two categories were grouped together, and
thus represented a total of 64 cases of HSIL samples.
Statistical methods
Outcomes of HPV test and histological diagnosis were
expressed as counts and percentages. Low estimate of the
vaccine impact was calculated as the prevalence of HPV
genotypes (HPV 6/11/16 and 18 for the quadrivalent, and
HPV 6/11/16/18/31/33/45/52 and 58 for the nonavalent
vaccine), alone or in association, by excluding the presence
of any other HPV type; high estimate was calculated as the
prevalence of HPV genotypes (HPV 6/11/16 and 18 for the
quadrivalent, and HPV 6/11/16/18/31/33/45/52 and 58 for
the nonavalent vaccine) alone or in association, also in the
presence of any other HPV type. The absolute additional
potential impact of the nonavalent vaccine, i.e., the propor-
tion of additional cases potentially prevented by the nona-
valent vaccine compared to the quadrivalent vaccine, was
calculated as (nnonavalent-nquadrivalent)/N £ 100, with n being
the number of lesions potentially prevented and N the total
number of lesions. The relative additional potential impact
of the nonavalent vaccine compared to the quadrivalent vac-
cine was calculated as (nnonavalent-nquadrivalent)/nquadrivalent£ 10010.
The chi-square test was used to assess the association
between categorical variables; z-test for proportions was
used to calculate 95% Conﬁdence Intervals (CIs) of the
quadrivalent and the nonavalent vaccine coverage on HSIL,
as well as of the absolute and relative additional impact of
the nonavalent vaccine compared to the quadrivalent vac-
cine. The impact of nonavalent HPV vaccine compared to
the quadrivalent vaccine was considered statistically signiﬁ-
cant if 95% CIs were not overlapping. The data were ana-
lyzed by means of Stata/SE 14.0.
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